anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Sepsis is a systemic inflammatory syndrome that can lead to multiple organ dysfunction and life-threatening complications. Sepsis-induced myocardial dysfunction (SIMD) has been confirmed to be present in half of patients with septic shock, increasing their mortality rate to 70-90%. The pathogenesis of SIMD is complex, and no specific clinical treatment has yet been developed. Caloric restriction mimetics (CRM), compounds that simulate the biochemical and functional properties of CR, can improve cardiovascular injury by activating autophagy. This study investigated the effect of a new type of CRM which can induce hypoxia, the SGLT nonspecific inhibitor phlorizin on SIMD.
MATERIALS AND METHODS: In vivo, phlorizin was administered at 1 mg/kg/day intragastrically for 28 days. In vitro, AC16 was treated with 120 μM phlorizin for 48 h. Echocardiography was used to assess cardiac function. Myocardial injury markers were detected in serum and cell supernatant. Western blotting was employed to detect changed proteins associated with apoptosis and autophagy. Immunofluorescence, immunohistochemistry, co-immunoprecipitation, molecular docking, and other methods were also used to illustrate cellular changes.
RESULTS: In vivo, phlorizin significantly improved the survival rate and cardiac function after sepsis injury, reduced markers of myocardial injury, inhibited myocardial apoptosis and oxidative stress, and promoted autophagy. In vitro, phlorizin alleviated the apoptosis of AC16, as well as inhibited oxidative stress and apoptotic enzyme activity. Phlorizin acts on autophagy at multiple sites through low energy (activation of AMPK) and hypoxia (release of Beclin-1 by Hif-1α/Bnip3 axis), promoting the formation and degradation of autophagosomes.
CONCLUSION: We indicated for the first time that phlorizin could inhibit glucose uptake via GLUT-1 and conforms to the metabolic characteristics of CRM, it can induce the hypoxic transcriptional paradigm. In addition, it inhibits apoptosis and improves SIMD by promoting autophagy generation and unobstructing autophagy flux. Moreover, it affects autophagy by releasing Beclin-1 through the Hif-1α/Bnip3 axis.
Steroid 5α reductase 2 (SRD5A2) converts testosterone to dihydrotestosterone and is crucial for prostatic development. 5α reductase inhibitors (5ARI) reduce prostate size in benign prostate hyperplasia (BPH) and ameliorate lower urinary tract symptoms secondary to BPH. However, the mechanisms of 5ARI functioning are still not fully understood. Here, we used a Srd5a2-/- mouse model and employed single-cell RNA sequencing to explore the impact of SRD5A2 absence on prostate cellular heterogeneity. Significant alterations in luminal epithelial cell (LE) populations were observed, alongside an increased proportion and proliferative phenotype of estrogen receptor 1 (ESR1)+ LE2 cells, following an SRD5A2-independent ESR1 differentiation trajectory. LE2 cells exhibited enhanced estrogen response gene signatures, suggesting an alternative pathway for prostate growth when SRD5A2 is absent. Human prostate biopsy analysis revealed an inverse correlation between the expressions of SRD5A2 and LE2 markers (ESR1/PKCα), and an inverse correlation between SRD5A2 and the clinical efficiency of 5ARI. These findings provide insights into 5ARI resistance mechanisms and potential alternative therapies for BPH-related lower urinary tract symptoms. © 2024 The Pathological Society of Great Britain and Ireland.
A Septin4 mutant gene and a pharmaceutical use thereof. Provided is a Septin4 mutant or an active fragment thereof. Compared with wild-type Septin4, the Septin4 mutant or the active fragment thereof comprises a mutation of K174R. Also provided is a pharmaceutical composition, the pharmaceutical composition comprising the Septin4 mutant or the active fragment thereof. Also provided is a use of the Septin4 mutant or the active fragment thereof or the pharmaceutical composition in preparation of a drug for preventing or treating hypertensive renal injury. Post-translational modification of acetylated proteins is combined with hypertensive renal injury, thereby providing an idea for designing a hypertensive renal treatment regimen and a targeted drug.
A Clostridium histolyticum collagenase CoIH (Glu451Asp) melts adipose tissue when injected into selected regions of the body. This protein product melts fat pads effectively in fat rat experiments, with very little side effects. Very little hemorrhage was observed. We also invent a new version of CoIH mutant by linking a peptide motif CKGGRAKDC-Gx (X is varying from 2 to 6 Gs) in front of CoIH (Glu451Asp) (called topical CoIH-FM), which can target to white fat vasculature. By combining with novel transdermal technology (such as Hydroxysome technology), we develop a topical protein cream that can melt fat. This product can be used as cellulite cream and for chemical liposuction. This topical CoIH-FM can also be injected into adipose tissue as a replacement for liposuction or as an adjunct method with liposuction. Since raise scar is formed by overgrowth of collagen, our topical CoIH-FM cream is shown to have application in scar reduction.
The present invention provides a sustained-release aromatic, characterized in that the aromatic comprises at least one perfume derivative as an active component selected from glycosides of perfumes, phosphoric acid ester derivatives of perfumes, amino acid derivatives of perfumes and carboxylic acid derivatives of perfumes, and contains no enzyme or acid which decomposes the perfume derivative, wherein the perfume derivative is decomposed by bacteria usually present on the skin or yeast to release a perfume component to exhibit aroma. The present invention also provides a method for the detection of micro-organisms using the aforesaid sustained-release aromatic. As the sustained-release aromatic of the present invention releases a perfume component only when it is decomposed by micro-organisms such as bacteria usually present on the skin or yeast, the amount of perfumes to be used can be extremely reduced. The sustained-release aromatic of the present invention is also excellent in keeping aroma. The stability with the passage of time of the sustained-release aromatic of the present invention is much better than that of the prior art because the perfume component is contained in the form of derivative. The sustained-release aromatic of the present invention is useful for applications on the skin, head skin or hair of human beings or animals, on clothes, or in drinks and foods, or as an indicator for detecting micro-organisms.
Cholesterol is treated with non-gaseous oxidizing agents to produce provitamin and is irradiated to produce vitamin.  The treatments may be successive.  Oxidizing agents mentioned are hydrogen peroxide, benzoyl peroxide, eosin and chromic anhydride. The cholesterol may be rendered free from provitamin by conversion into the dibromide, recrystallizing the dibromide, removing the bromine and recrystallizing the cholesterol. Examples describe the oxidation treatment with hydrogen peroxide with simultaneous and successive irradiation respectively, and with benzoyl peroxide.  It is stated that chromic anhydride in glacial acetic acid may be used in quantity one-fifth to one-sixth of the quantity of cholesterol.
The activation of hepatic stellate cells (HSCs) is central to the occurrence and development of liver fibrosis. Our previous studies showed that autophagy promotes HSC activation and ultimately accelerates liver fibrosis. Unc-51-like autophagy activating kinase 1 (ULK1) is an autophagic initiator in mammals, and N 6-methyladenosine (m 6A) modification is closely related to autophagy. In this study, we find that the m 6A demethylase fat mass and obesity-associated protein (FTO), which is the m 6A methylase with the most significant difference in expression, is upregulated during HSC activation and bile duct ligation (BDL)-induced hepatic fibrosis. Importantly, we identify that FTO overexpression aggravates HSC activation and hepatic fibrosis via autophagy. Mechanistically, compared with other autophagy-related genes, ULK1 is a target of FTO because FTO mainly mediates the m 6A demethylation of ULK1 and upregulates its expression, thereby enhancing autophagy and the activation of HSCs. Notably, the m 6A reader YTH domain-containing protein 2 (YTHDC2) decreases ULK1 mRNA level by recognizing the m 6A binding site and ultimately inhibiting autophagy and HSC activation. Taken together, our findings highlight m 6A-dependent ULK1 as an essential regulator of HSC autophagy and reveal that ULK1 is a novel potential therapeutic target for hepatic fibrosis treatment.
Diabetics and non-diabetics with or without known CV disease who are admitted in the Department of Cardiology in the University Hospital of Ioannina and the Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. The study will include subjects who 1) have suspected CAD and undergo a scheduled diagnostic angiogram for clinical reasons, and 2) are hospitalized because of an acute coronary syndrome and thus undergo diagnostic angiography (with or without previous history of CAD).
Cluster 1 is the first OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the sixth month of the trial. Cluster 1 will be a 'no intervention' arm in the first 6 months of the study, and will cross-over to an experimental arm for months 6-24.
Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
Rituximab (RTX) is used in the treatment of malignant non-Hodgkin's indication for which it has been authorized since 1997 and why it is considered effective and well tolerated. Rituximab is also effective and well tolerated in combination with methotrexate in severe rheumatoid arthritis (RA) refractory to anti-TNF. To date, the RA is the only autoimmune disease in which rituximab has proven efficacy in randomized trials and has obtained authorization in this indication. There are also data from the literature, for the benefit of rituximab in other autoimmune diseases like Lupus, cryoglobulinemia associated to Hepatitis C or Sjogren's disease.

Immune Thrombocytopenia (ITP) is an autoimmune disease in which there is thrombocytopenia due in part to destruction of platelets by autoantibodies. In adults, the disease is most often chronic and in the most severe forms, the treatment of choice is splenectomy. Rituximab was suggested during chronic ITP when used with 4 weekly infusions of 375 mg/m2, 60% of patients achieve an immediate response and 30 to 40% a prolonged response. These encouraging results and the apparent good tolerance advocate for using rituximab as first-line treatment for patients refractory to splenectomy. In France, Afssaps - French Health Products Safety Agency has recently issued a temporary protocol processing to authorize rituximab in this indication. Nevertheless, many questions remain unresolved, including the tolerance of long-term treatment and the risk of late relapse in responders. This justifies the creation of this register, whose establishment is recommended by Afssaps - French Health Products Safety Agency.
PURPOSE:To obtain a crystallized calcium phosphate glass for dental material having transparent and beautiful appearance, by melting a calcium phosphate mixture having specific atomic ratio of Ca/P under normal pressure, cooling the molten mixture, and again melting under reduced pressure. CONSTITUTION:A Calcium phosphate mixture having an atomic ratio (Ca/P) of 0.35-1.7 is melted under atmospheric pressure, and cooled to obtain glass. The glass is melted again under reduced pressure of about <=100Torr, returned to the atmospheric pressure, and cast by a lost-wax process. The cast glass is crystallized by beat-treatment. The water, air, carbon dioxide gas, etc. existing in the glass can be removed, and transparent feeling can be attained by the crystallization of the glass. The damage of the crucible and the furnace can be decreased compared with the case of direct melting.
PCT No. PCT/JP87/00618 Sec. 371 Date Apr. 20, 1988 Sec. 102(e) Date Apr. 20, 1988 PCT Filed Aug. 20, 1987 PCT Pub. No. WO88/01170 PCT Pub. Date Feb. 25, 1988.An external adhesive preparation comprising a steroid for treatment of skin diseases in admixture with an adhesive gel base comprising as essential components a water-soluble high molecular weight compound, water and a water-retaining agent. The external adhesive preparation is useful for treatment of skin diseases by applying the preparation spread on a soft support directly to diseased parts on the skin, thereby administering the contained steroid to the skin.
After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and aprepitant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and aprepitant, respectively.
PURPOSE: A composition containing procyanidin B3 compound or condensed tannin compound for treating atopic dermatitis is provided to reduce eosinophil number and IgE level. CONSTITUTION: A pharmaceutical composition for preventing or treating atopic dermatitis contains pharmaceutically effective amount of a compound of chemical formula 1 or 2 and pharmaceutically acceptable carrier. The composition is produced in the form of external use skin formulation. The external use formulation is powder, gel, ointment, cream, liquid or aerosol. A cosmetic composition for relieving atopic dermatitis contains cosmetically effective amount of the compound of chemical formula 1 or 2 and cosmetically acceptable carrier. The composition is used in the form of solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation or spray.
Dopamine, a type of neurotransmitter, is the brain's "feel good" chemical. The amount of dopamine in the body may be an important factor in how cocaine addicts respond to treatment. Disulfiram, like cocaine, enhances dopamine activity. Upon taking disulfiram, subsequent intake of cocaine may elevate dopamine to excessive levels that produce extreme discomfort. DBH is an enzyme that breaks down dopamine. A particular variation in the DBH gene can affect the amount of dopamine that is released in the body. Therefore, cocaine addicts with varying DBH genes may respond differently to treatment. The purpose of this study is to compare the effectiveness of disulfiram in preventing relapse among methadone-maintained individuals addicted to both cocaine and opioids who may have different DBH genes.

This 17-week study will begin with a 2-week methadone stabilization period. Participants will then be randomly assigned to receive a daily dose of either 250 mg of disulfiram or placebo for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving study medication at Week 14, at which point they will undergo a 4-week methadone detoxification period. Participants will report cocaine and other drug use, as well as any cocaine cravings that they experience. Cocaine levels will be monitored throughout the study with urine tests. The DBH gene of each participant will be examined to determine its specific make-up and any particular variations.
PROBLEM TO BE SOLVED: To provide wild-strains of Chikungunya virus isolated from patients exhibiting severe forms of infection and stemming from a human arbovirosis epidemy, and to provide polypeptide sequences and fragment thereof derived from their genome, the polynucleotide encoding same and their use as diagnostic products, as vaccine and/or as immunogenic compositions.SOLUTION: Wild strains 06.49 of Chikungunya virus (CHIKV) that can be infected in a human cell by in vitro are separated and refined. A polynucleotide is separated and refined. A vector includes the fragment of the polynucleotide. A host cell includes the vector. A refined polypeptide is encoded by the fragment of the polynucleotide. A monoclonal or polyclonal antibody specifically unites with the polypeptide. The component is used for the in vitro detection of CHIKV relating to an arbovirus syndrome.
App to facilitate exercises for 3 times a week for 12 weeks. The app includes physical therapist-designed exercises that are modified using an algorithm to the participants physical capabilities and PD status. Exercises include strengthening, balance, range of motion, and endurance type exercise.
The training intervention groups will undergo the same program with the only difference being the interventional hamstring exercise. The program will consist of a 2-week acclimatization period followed by 4-weeks of progressive training. During the acclimatization period, the relative intensity will be lower compared to the 4-week progressive training to ensure each participant performs the exercise with proper technique. During the subsequent progressive training weeks, the participants will perform the NHE without the bands.
The recommended dosage of KRAZATI as a single agent or in combination with cetuximab is 600 mg orally twice daily until disease progression or unacceptable toxicity.

Refer to the cetuximab prescribing information for cetuximab dosage information [see Clinical Studies (14.2)].

Take KRAZATI at the same time every day with or without food [see Clinical Pharmacology (12.3)]. Swallow tablets whole. Do not chew, crush or split tablets.

If vomiting occurs after taking KRAZATI, do not take an additional dose. Resume dosing at the next scheduled time.

If a dose is inadvertently missed, it should be skipped if greater than 4 hours have elapsed from the expected dosing time. Resume dosing at the next scheduled time.
Chronic cholestatic damage is associated to both accumulation of cytotoxic levels of bile acids and expansion of adult hepatic progenitor cells (HPC) as part of the ductular reaction contributing to the regenerative response. Here, we report a bile acid-specific cytotoxic response in mouse HPC, which is partially impaired by EGF signaling. Additionally, we show that EGF synergizes with bile acids to trigger inflammatory signaling and NLRP3 inflammasome activation in HPC. Aiming at understanding the impact of this HPC specific response on the liver microenvironment we run a proteomic analysis of HPC secretome. Data show an enrichment in immune and TGF-β regulators, ECM components and remodeling proteins in HPC secretome. Consistently, HPC-derived conditioned medium promotes hepatic stellate cell (HSC) activation and macrophage M1-like polarization. Strikingly, EGF and bile acids co-treatment leads to profound changes in the secretome composition, illustrated by an abolishment of HSC activating effect and by promoting macrophage M2-like polarization. Collectively, we provide new specific mechanisms behind HPC regulatory action during cholestatic liver injury, with an active role in cellular interactome and inflammatory response regulation. Moreover, findings prove a key contribution for EGFR signaling jointly with bile acids in HPC-mediated actions.
The invention relates to novel products produced from the conjugation of flavonols with cysteine. The novel molecules are obtained from polyphenolic plant extracts by means of conjugation with the natural cysteine amino acid. In this way, novel products with antioxidant/antiradical properties are generated which can be used as agents to protect the body against disorders such as cancer, cardiovascular diseases and premature ageing. The resulting pure molecules are more effective antioxidants than the individual components (flavonols and cysteine) thereof. The concept of novel products derived from cysteine having antioxidant properties extends from the pure molecules to mixtures thereof, thiolysis crudes and partially purified fractions. The invention also relates to the method of isolating and purifying the novel compounds using complex mixtures.
A system for processing a fluid sample includes a tube and a piston. The tube has an open end and a closed end, and a volume defined therebetween. The volume is further defined by an interior surface of the tube. The tube is designed to receive a collection media holding the fluid sample. The piston has a first side and a second side, and is designed to be inserted into the tube via the open end of the tube. The piston is further designed to be translatable within the tube, and to compress the collection media between the closed end of the tube and the first side of the piston such that at least a portion of the fluid sample is removed from the collection media and driven to the second side of the piston.
A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
PURPOSE: This pilot study aimed to determine whether the Henkin olfactory test discriminates between the olfactory function of patients with olfactory loss and healthy individuals, and whether the Henkin test is correlated with a validated psychophysical olfactory test.
METHODS: Participants underwent olfactory testing using the modified Henkin test (including detection [DT] and recognition [RT] thresholds, magnitude estimation [ME], and hedonic ratings [H], for four different odors) and the extended "Sniffin' Sticks" test battery (odor detection, discrimination, identification).
RESULTS: Forty-four individuals (28 women, aged 19-81 years, mean: 39 years) were included. Twenty-three were healthy (mean age: 38 years) and 21 had olfactory dysfunction (OD) (mean age: 40 years). OD patients had worse mean DT, lower composite RT, and lower ME ratings. Mean and individual odor H ratings were not significantly different between the groups. Most individuals were classified as hyposmic when using the prescribed classification by Henkin, with only very few satisfying the stringent criteria of anosmia and normosmia. Modified Henkin subtests were all positively correlated with each other and with the "Sniffin' Sticks", except for Unpleasant Mean H which was only correlated with Pleasant Mean H; and Pleasant mean H which was not correlated with mean DT scores.
CONCLUSION: The Henkin test is able to separate between OD patients and controls. However, modifications to the conduct of this test may be required. Studies that used this test should be carefully interpreted.